RammurtiKambleMD

Oncology • Houston, TX

Associate Professor, Center for Gene Therapy, Baylor College of Medicine

Join to view full profile

Dr. Kamble is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kamble's full profile

Already have an account?

Office
6565 Fannin St
Houston, TX 77030
Phone+1 713-441-1450

Fax+1 713-793-1232

Education & Training

Methodist Le Bonheur Healthcare/CentralResidency, Internal Medicine, 1999 - 2001
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1997 - 1999
J.L.N. Medicine Coll, Ravishankar Shukla UniversityClass of 1991

Certifications & Licensure

TX State Medical License 2006 - 2026
OK State Medical License 2001 - 2006
AR State Medical License 2001 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Rituximab for GVHD Start of enrollment: 2007 Jun 01
Withdrawn
Phase 2
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) Start of enrollment: 2007 Jun 01
Terminated
Phase 1, Phase 2
Phase I Study of CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia [CRETI-NH] Start of enrollment: 2007 Jan 01
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.
Ibrahim N Muhsen, Kristen E Shaver, Tao Wang, Mengfen Wu, Premal Lulla
Transplantation and Cellular Therapy. 2024-12-01
1 citations
Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study.
Justine Kahn, Ruta Brazauskas, Stephanie Bo-Subait, David Buchbinder, Betty K Hamilton
The Lancet. Child & Adolescent Health. 2024-10-01
2 citations
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Dawn Maze, Murat O Arcasoy, Ryan Henrie, Sonia Cerquozzi, Rammurti Kamble
Bone Marrow Transplantation. 2024-02-01

Abstracts/Posters

T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients
Rammurti Kamble, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients with Multiple Myeloma
Rammurti Kamble, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018